- Dermatology biotech
- Dermira was studying the drug in kids over 9 years old to see if it could reduce the number of inflammatory and non-inflammatory lesions on that person's skin compared to a control arm.
- Dermira, which had a market cap of about $1 billion when markets closed on Friday was down as much as 64% on Monday in pre-market trading.
- "We are surprised and extremely disappointed by the results of the Phase 3 program," Dermira CEO Tom Wiggans said in a news release.
- The company is also developing treatments for hyperhidrosis, otherwise known as excessive sweating, and atopic dermatitis.
ADVERTISEMENT
An experimental acne drug just failed two key clinical trials — and the stock's getting obliterated (DERM)
Dermatology biotech Dermira said on Monday that its experimental drug to treat acne failed two key clinical trials.
ADVERTISEMENT
FOLLOW BUSINESS INSIDER AFRICA
ADVERTISEMENT
Recommended articles
Changes in the net worth of Africa's 10 richest men since January
France to back Morocco's power link to Western Sahara
Kenya’s Ruto backs Zimbabwe’s ZiG currency for economic prosperity
Here’s another reason Nigeria is losing billions of dollars annually
Top 10 African countries with the lowest fuel prices in April 2024
How SafeHamsters unlocks the potential of crypto betting| Insider Tips
A look into the diverse tax reforms being implemented across Africa
Dubai firm to lend South Sudan $12.9 billion in exchange for 20 years oil repayment